Mark Kiel
About Mark Kiel
Mark J. Kiel, CSO and Co-Founder, is a distinguished leader in cancer genomics, known for his contributions to cancer biomarkers and therapeutic targets, and his expertise in genomic data for clinical decision-making.
CSO & Co-Founder Mark J. Kiel
Mark J. Kiel serves as the Chief Scientific Officer (CSO) and Co-Founder of his current organization. With a strong background in cancer genomics, his work has contributed significantly to the identification of novel biomarkers and therapeutic targets. His expertise in the application of genomic data for clinical decision-making plays a crucial role in the company's strategic initiatives.
Education and Expertise in Molecular Medicine and Genetics
Mark J. Kiel holds a PhD in Molecular Medicine and Genetics from the University of Michigan. He further honed his expertise by completing a postdoctoral fellowship in clinical chemistry at the Washington University School of Medicine. With over 15 years of experience in cancer genomics, his scientific contributions are well-regarded in the field.
Leader in Genomics and Precision Medicine
Mark J. Kiel is recognized as a leader in applying genomic data for clinical decision-making. His contributions to genomics and precision medicine have earned him invitations to speak at numerous national and international conferences. He continues to influence the field with his insights and research findings.
Editorial Board Memberships and Professional Associations
Mark J. Kiel serves on the editorial boards of several journals specializing in genomics and clinical chemistry. He is an active member of the American Association for Cancer Research and the Association for Molecular Pathology. These roles underline his leadership and commitment to advancing genomic research and clinical applications.
Contributions to Cancer Genomics Research
With over 35 peer-reviewed articles co-authored in the field of genomics, Mark J. Kiel's research has contributed significantly to the scientific community. His work focuses on identifying novel cancer biomarkers and therapeutic targets, which play a critical role in advancing cancer treatment and patient care.